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 ABSTRACT
Chronic kidney disease (CKD) has a high clinical and socioeconomic impact and is often associated with mul-
timorbidity. Improved treatment has allowed an increase in patient survival, but patient life expectancy remains 
limited. The disease course has a continuum of lesion, stage and treatment transitions. The focus is often placed 
on treatment modality, disregarding the course of a CKD patient’s disease. In addition, patient management in 
transitions of modalities of renal replacement therapy (RRT) can also be a vector for improving clinical 
outcomes.
The transition between different types of CKD treatment and the transition of care from paediatric to adult 
team are critical processes throughout the life of a CKD patient. In the therapeutic transition, there is the need 
to identify better predictors of success in allocating patients with stage 5 CKD to their first dialytic modality in. 
There is a risk of early mortality in the induction period of dialysis, particularly of the elderly in extracorporeal 
dialysis regimens. Doubt remains in decision making about the ideal timing to establish the transition to renal 
replacement therapy and its most appropriate type. Transfer between dialytic modalities also calls for opportune 
and integrated policies protecting vascular resources. Renal transplantation is considered the optimal renal 
replacement therapy; however, transplant failure or the side effects of immunosuppression are threats to con-
sider, which may redirect these patients back to dialysis and involves a re -evaluation of the patient’s status. Also, 
end -of -life care and decision making between initiating renal replacement therapy or maintaining conservative 
management are a challenge in the elderly.
This review identifies the main challenges in these transitional processes, raising awareness of areas in need 
of improvement in patient care. The aim should be to achieve a more comprehensive and appropriate health 
management than a limited focus on CKD modality treatment.
Keywords: Chronic kidney failure; Renal replacement therapy; Conservative non -dialytic treatment; Quality of 
life; Transitional care; Continuity of patient care.
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 INTRODUCTION
Chronic kidney disease (CKD) is an important public 
health problem, with increasing prevalence and health 
costs, and associated with poor clinical outcomes, such 
as decreased quality of life, progression to renal failure, 
all -cause and cardiovascular mortality1-4.
A global improvement in treatment and outcomes of 
CKD has been achieved but the threat of patient limited 
survival with high burden of care and costs still looms. 
Several insufficiencies and problems are identified in CKD 
stages and transition process, as shown in Tables I -VII.
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Table IV
Identified problems in the transition between dialysis modalities
Inadequate allocation of the patient to the modality, with mismatch of 
expectations
Urgent transitions with interruption of care management, generating clinical risk
Inadequate permanency in a dialysis modality or late transition, with conse-
quences on survival
Absence of adequate planning of PD to HD transition, with use of precarious 
vascular access (CVC)
Complications related to PD, motivating transition of modality: repetitive 
peritonitis and fungal peritonitis, dialysis inadequacy (loss of RRF, deteriora-
tion of peritoneal membrane function)
Complications related to HD, motivating transition of modality: difficulties in 
vascular access, severe or refractory hypotension or other symptomatology, 
malnutrition associated with conventional HD
Vascular accesses manipulation till exhaustion without considering alternative 
modality of dialysis 
Impact of dialytic modality on quality of life and development of depression
Lack of patient’s course disease management 
Table VII
Identified problems in the transition to end -of -life and palliative care
Lack of holistic conservative care programs
Lack of legal framework that allows the application of these programs and 
supports clinical decisions
Lack of social support, with frequent abandonment of these patients in 
hospitals 
Lack of financial support for the development and implementation of these 
programs
Insufficient institutional support
Inadvisable dialysis in some patients of this group, in the absence of suffi-
ciently specific or life-threatening clinic or symptomatology 
Often maladjusted expectations of the family 
Lack of human resources and training in palliative treatment
Silo management (disaggregation of investment in Hospital Units / General 
and Family Medicine Units / Palliative Care Units / Social Partners)
 
Table VI
Identified problems in the transition back to dialysis after renal trans-
plantation
Disaggregation of care between dialysis and transplantation centres
Little focus on pre -dialytic care with late referral for evaluation for dialysis
Overvaluation of graft function preservation, with risks of immunosuppres-
sion
Sudden and unpredictable loss of graft function
State of immunosuppression and chronic inflammatory state by the presence 
of dysfunctional graft
Patient’s resistance to transition to dialytic therapy
Internal crisis process with decreased quality of life and increased levels of 
depression
 
Table V
Identified problems in the transition from dialysis to renal transplantation
Time on dialysis before transplantation (more post -transplant adverse out-
comes)
Significant increase in quality of life with risk of distorted perception of 
absence of disease and honeymoon effect at the beginning of the transi-
tional period: higher propensity for risk behaviours in CKD management
Risks of non -adherence and avoidance of preventive measures (renal injury 
/ cardiovascular disease / infection)
 
Table III
Identified problems in the transition to de novo dialysis therapy
Late referral and diagnosis of CKD patients
Insufficiencies in the informed consent process
Lack of adequate planning, without timely access creation for the initiation 
of dialysis therapy
Complications associated with the high rate of CVC use for HD initiation
Relatively small number of patients initiating dialysis with PD
Cognitive, hemodynamic and functional impact of HD in older and fragile 
patients
Risk of early mortality with HD in older and fragile patients
Shortage / absence of family and social support (real or perceived)
 
Table II
Identified problems in the transition to pre -emptive transplantation
Unawareness of the benefits and devaluation of transplantation as compared 
to dialysis (non -experience of dialysis limitations and suffering), with conse-
quences on compliance, graft and patient survival 
Difficulty adapting to the new condition and misperception of this RRT 
strategy 
 
Table I
Identified problems in the transition from paediatric to adult care
Fixed age timing for transfer, independent of mental maturity
Unstable biopsychosocial context, typical of the age group
Cognitive impairment associated with CKD
Non -adherence to treatment, with lack of understanding and consequence 
recognition
Patients’ and/or families’ reluctance to adhere to the transition process 
(possible lack of family support)
Gaps of communication between the two health care teams and between 
these and the patient and family
Different composition and treatment focus of the adult nephrology team 
compared to the paediatric team
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Quality control processes are often focused on con-
troversial indicators lacking patients’ perceptions of 
quality and an integrated approach to the modalities 
of treatment. Further, the focus is often placed on treat-
ment modality, disregarding the course of a CKD 
patient’s disease.
We propose that the management of transitions in 
CKD treatments should also be included in the quality 
improvement processes of nephrology departments as 
a vector for improving clinical outcomes. The aim of 
this review is to present a critical appraisal of these 
opportunities for improvement over the course of a 
CKD patient’s disease.
  CHRONIC KIDNEY DISEASE  
AND RENAL REPLACEMENT THERAPY 
OPTIONS
Prevention of acute renal lesions is mandatory and 
there should be a task force in public health and hos-
pitals aiming toward nephroprotection. The progression 
of CKD may not have a steady linear decline and show 
a heterogeneous trajectory5. Estimated glomerular fil-
tration rate (eGFR) trajectories are independent predic-
tors of advanced stage CKD, with clinical implications 
for the timing of RRT initiation5,6. In patients with 
advanced stage CKD, fragmentation of care, inadequate 
vascular accesses, lack of focus on the management of 
comorbidities and absence of preventive care are obsta-
cles that result in poor clinical outcomes and higher 
costs7. Iatrogenic episodes leading to acute kidney 
injury, hospitalization or crisis with loss of functional 
abilities are frequent. A disease management program 
aims to improve results with cost savings7, with benefits 
in the progression of CKD, risk of renal failure and quality 
of life3. In such a program, multidisciplinary collabora-
tion is fundamental7. The nephrologist plays a leading 
role, ensuring coordinated care7. The nurse is essential 
in the integration of care, in follow -up and as a central-
izing care member among different physicians, other 
health professionals and the patient7.
A management plan initiated in stage 3 -4 CKD and/or 
a specific low clearance consultation in interaction with 
the primary care physician are examples of transition 
care optimization measures. This plan should include:
1.  Flagging up of clinical and social risk situations 
and timely referral to multidisciplinary team 
members.
2.  Systematic nephroprotection (anticipation of clini-
cal risk, patient and family education, eviction of 
drug redundancy and adverse effects, nephrotoxic 
eviction, eviction of puncture of vascular accesses 
in the non -dominant limb for preservation of vas-
cular patrimony).
3.  Efficient post -discharge hospital communication 
with improved rehabilitation care.
4.  Use of non -presential contact to complement sup-
port to patients and families in the post-
-hospitalization phase.
5.  Assessment of patient and family expectations 
about the disease and its treatment modalities.
6.  Evaluation of fragilities and comorbidities with 
prognostic impact that imply limited life expec-
tancy / quality of life under dialysis and equation 
of non -dialytic support treatment.
7.  Optimization of palliative care measures when 
indicated.
Presently, the financial constraint of the country has 
limited this intervention; however a long -range vision 
may show that investment in this critical transition 
phase can save costs related to the inexistence of this 
management process.
RRT therapies in end -stage renal disease include renal 
transplantation, haemodialysis (HD) and peritoneal dialy-
sis (PD)8. Upon reaching stage 4 CKD, patients should 
discuss RRT options with the nephrologist for a timely 
preparation8, in full respect of the informed consent 
process of choice of therapies. There is a recognized 
higher risk of death in the first 3 -6 months after initiation 
of RRT, whether dialysis or transplantation is involved9.
Renal transplantation allows longer survival and better 
quality of life than dialysis, and pre-emptive transplanta-
tion is preferable8. However, in the present system of 
renal graft allocation (from deceased donors), the previ-
ous time on dialysis is scored to mitigate the effect of 
pre -transplantation waiting time of many dialysis 
patients. Therefore, to apply the strategy of pre -emptive 
renal transplantation more effectively, a task force on 
living organ donation must be put forward, both in 
nephrology and in society. According to KDIGO guide-
lines10, pre-emptive transplantation should be consid-
ered at eGFR <20ml/min/1.73m2 with evidence of pro-
gressive and irreversible CKD in the last 6 -12 months.
The clinical guidelines10 suggest that dialysis should 
be initiated in the presence of signs or symptoms attrib-
utable to renal failure, inability to control volume status 
or blood pressure (BP), progressive deterioration of 
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nutritional status refractory to dietary intervention or 
cognitive impairment. This often occurs with eGFR of 5 
to 10ml/min/1.73m210; however, the decision to initiate 
dialysis should not depend on an isolated numerical 
value11. For patients who choose HD, arteriovenous fis-
tula (AVF) is the vascular access preferred due to the 
lower rates of infection, thrombosis and interventions 
to maintain patency8. The benefit associated with longer 
or more frequent sessions than in conventional HD has 
resulted in increased interest in nocturnal HD, in-centre 
or at home8,12. PD is a good option for motivated adult 
patients capable of self -care and also those of paediatric 
age8 or when assisted PD is viable. Desirably, domiciliary 
therapies should be chosen whenever possible.
Conservative non -dialytic treatment (CNT) should 
be an option for elderly patients10 with expected short-
er survival due to severe comorbidities.
In the treatment trajectory (Fig. 1), changes in ther-
apy are common13 and should be anticipated13,14 
because the transition periods are associated with a 
state of patient greater vulnerability, a very high rate 
of adverse events and critical decision making15. How-
ever not all causes of transfer mean the same in terms 
of impact in global patient survival and more investiga-
tion should be focused on the best track of transfers 
to protect the patient.
  TRANSITION FROM PAEDIATRIC  
TO ADULT CARE
Transition from paediatric to adult care is a period 
of great anxiety for young patients and their parents16. 
The transition in this age group is associated with poor 
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Figure 1
Transition of care in CKD and examples of the challenges of each transition
QoL – quality of life; Hosp. – hospital. 
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outcomes, difficulties in self-management of CKD, 
decreased therapeutic compliance and increased avoid-
able hospitalizations16-18. In renal transplant adoles-
cents and young adults, there is also the risk of acute 
rejection, chronic graft loss or dysfunction due to poor 
compliance with immunosuppression16,19, which is 
independent of the transplantation age20. Non-
-adherence to medical treatment is the main cause of 
graft loss in adolescents, due to lack of understanding 
and consequence recognition20-22. The cognitive 
impairment and delayed cognitive development associ-
ated with CKD, although apparently subtle, may be an 
important contribution to poor adherence20.
These outcomes are not only related to the transi-
tion itself, but are mainly a reflection of the unstable 
biopsychosocial context of this age group16,22, between 
14 -24 years, who are still in the brain development and 
maturation process16,19,23. Patients transferred at an 
older age appear to have better outcomes20,22. There 
might also be a reluctance of patients and parents to 
leave paediatric care16.
In this transition, the patient is expected to be 
progressively more prepared to assume responsibility 
for the management of CKD16,18,23, with its medica-
tions, procedures and nutritional requirements19. 
In -centre HD patients appear to have worse CKD 
self-management abilities than those in dialysis 
home modalities19, but individualization is manda-
tory, taking into consideration patient mental ability 
and family context.
A paediatric unit is multidisciplinary, has psychosocial 
support, fewer patients, is more family oriented, con-
siders growth and development issues and has more 
experience in congenital anomalies of the kidney and 
urinary tract and other nephropathies that most com-
monly cause CKD in children and adolescents19,24,25. 
Sometimes follow -up in adult care has less support in 
their teams, is more individualized24 and requires 
greater autonomy, which is not possessed by the pae-
diatric age group shortly before transference16. Gaps 
of communication between the two teams or these 
and the patient and family are another barrier to suc-
cessful transition18.
In the face of the problems identified in this transi-
tion, summarized in table I, the implementation of a 
transition program between paediatric and adult care 
is identified as a major measure of optimization. This 
transition program consists of a well-structured pro-
cess, involving a multidisciplinary team of paediatric 
and adult nephrologists, leading to improved long -term 
outcomes16. Based on the clinical recommendations 
of the International Society of Nephrology and Inter-
national Paediatric Nephrology Association23 these 
programs should include:
1.  A health professional who oversees long -term 
planning and coordinates the remaining members 
of the team23.
2.  Early onset of the transition process, in Paediatric 
Nephrology with continuity and follow -up by the 
reference physician in adult Nephrology, until 
acquisition of self-management skills of CKD is 
optimized23.
3.  Active involvement of the patient and family23.
4.  Transfer during a period of stability, with effective 
communication ensured between the paediatric 
and adult teams16,23.
5.  Promoting access to peer support structures in 
the preparation19,23 and, above all, after transfer 
to an adult unit26.
6.  Annual assessment of the patient’s ability for tran-
sition and self -management skills of CKD19, so that 
it is possible to individualize the timing of transi-
tion, depending on the patient’s capabilities and 
maturity23, and not at a fixed age time.
7.  Interventions for the education and management 
of several areas of the disease (nutrition, BP, labo-
ratory results, drug management) whenever 
necessary19.
A transition clinic, where the young person is seen 
jointly by paediatric and adult nephrologists, shortly 
before transfer, is considered an ideal transition 
method23.
  TRANSITION TO PRE -EMPTIVE 
TRANSPLANTATION
Renal transplantation is considered the best RRT in 
eligible patients and is responsible for a greater 
improved quality of life than dialysis3,27,28. A renal 
transplant patient has longer life expectancy, feels bet-
ter, has more ability to continue working, and is less 
likely to be hospitalized3. Living donor transplantation 
has better outcomes, can be scheduled in time and be 
faster than deceased donor transplantation3. Renal 
transplantation is also the most cost-effective treat-
ment, although most health expenditures in RRT are 
directed at dialysis, because of the limitation of avail-
able organs4.
Transitions of care management in CKD: critical thinking and improving strategies
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Preparation for renal transplantation is best achieved 
when there is a clinically controlled progression 
between stages 4 and 5 of CKD11. Despite this, many 
patients achieve advanced stage CKD without the desir-
able preparation11.
Pre-emptive transplantation is the preferred RRT 
and avoids dialysis, which is in line with the current 
recognition that reducing the dialysis period has advan-
tages in quality of life, clinical outcomes and health 
costs27. Patients may experience renal transplantation 
in a very different way, depending on whether they 
have undergone a previous dialysis period or have gone 
through surgery with a functioning kidney27. Patients 
undergoing pre-emptive transplantation may not be 
aware of the benefits of transplantation as compared 
to dialysis and can also experience the suffering of 
transplantation, as a result of surgery or immunosup-
pressive therapy27. Compared to patients with previ-
ous dialysis, those undergoing pre-emptive transplan-
tation are more likely to have a lower perceived quality 
of life after transplantation and more difficulty adapt-
ing to their new condition, although they generally 
have a better level of physical health27.
The value of renal transplantation can vary consider-
ably, also among patients who performed it pre-emp-
tively, with descriptions of patients who considered it 
responsible for a deterioration of their well -being27. 
The patient’s perception of the impact of this RRT strat-
egy may be the result of the global variability of the 
pre-emptive transplant practice and this is important 
information, as it may have consequences for compli-
ance, graft and patient survival27.
Currently, only 2.6% of patients receive pre-emptive 
renal transplantation3, which implies an available living 
donor, generally a patient’s relative. Nevertheless, 
pre-emptive transplantation has a lower cost, is associ-
ated with longer graft survival and a lower rate of acute 
organ rejection, which gives the patient a survival 
advantage compared to transplantation after a previous 
dialysis period3.
Faced with these discrepancies (summarized in table 
II), the implementation of an educational program with 
coordination of care will optimize the process. It should 
integrate:
1.  Patient follow -up, favouring a clinically controlled 
progression of’ CKD between stages 4 and 5.
2.  Promotion of debate with the patient and his fam-
ily about the appropriate RRT options for his 
particular situation, including repeated clarifica-
tion of the advantages and commitments inherent 
for the patient in renal transplantation, and par-
ticularly pre-emptive transplantation3,27.
3.  Patient follow -up after the option for pre-emptive 
transplantation, with focus on compliance promo-
tion, education for nephroprotection and preven-
tion of CKD in the graft, in order to prevent its 
premature failure27.
4.  Promotion of live donor transplantation3, social 
valuation of organ donation and protection of the 
donor.
  TRANSITION TO DE NOVO DIALYSIS 
THERAPY
The onset of de novo dialysis, previously prepared 
and planned, is associated with better short - and 
long-term outcomes29. However, the onset of dialysis is 
often unplanned and complicated by temporary vascular 
access and sometimes without the possibility of provid-
ing the patient with their modality or location of choice30. 
This process of dialysis access creation, seldom optimal, 
lowers the quality of care and increases its cost3.
Studies on patients’ opinions show that up to 30% 
would opt for PD4. Moreover, participation in some edu-
cational programs on dialysis results in a greater probabil-
ity of PD, a lower probability of HD with catheter and 
lower mortality in the first 90 days after initiating dialysis3. 
PD has shown recent outcome improvement and should 
be made available to patients with the ability to perform 
the procedure11. Also, in patients who are unable to per-
form auto -dialysis should be assisted in the modality they 
opt, as for example assisted PD. Compared to in-centre 
HD, PD as the initial modality of RRT is associated with 
preservation of RRF, better survival in the first one to two 
years, is more cost -effective and allows patients’ greater 
rehabilitation[31]. Therefore, there is an effort to increase 
the choice for this home modality31. However, a more 
focused peritoneal access implantation program is need-
ed to support this strategy and avoid early access com-
plications that threaten immature PD programmes.
Patients who receive comprehensive education on 
CKD more often choose PD or home HD11,32. The 
obstacles to these options are patients’ and families’ 
disinterest and lack of social support32. The choice of 
home HD is associated with younger age, job mainte-
nance and absence of language barrier32. In fact, home 
dialysis is a cost -effective RRT, associated with better 
quality of life compared to in-centre HD, but it requires 
the patient’s ability to perform dialysis himself32.
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It is fundamental to adequately prepare the patient 
with CKD, regardless of the dialytic modality of choice, 
when reaching advanced stage CKD11. The HD option has 
challenges, such as several weekly treatments, risk of rapid 
fluid and electrolyte shifts, complications of comorbidities, 
vascular access and reduced life expectancy33 and often 
unprevented acute kidney injury that accelerates the tra-
jectory of renal failure. The onset of HD is unscheduled in 
up to 50% of patients, mainly due to late diagnosis or 
referral34. This insufficient preparation results in a low 
frequency of AVF, increasing HD with central venous cath-
eter (CVC), which results in an increase in catheter-asso-
ciated infections, hospitalizations, morbidity, mortality and 
higher costs3,11,30,34. A further negative effect is the lower 
number of patients initiating PD11. Fluck29 advocates the 
use of continuous ambulatory PD as transient dialysis 
therapy in the context of unplanned initiation of dialysis. 
In the HD option, PD would be a resource option during 
the maturation of AVF, which would involve acute place-
ment of peritoneal catheter (possible obstacle)29,30. The 
authors mentioned that peritoneal catheter placement 
can be readily available with initial safety rates comparable 
to those of temporary CVC29, with lower risk of bacterae-
mia, sepsis and the hemodynamic instability associated 
with extracorporeal dialysis. It has been demonstrated 
that the coordination of pre-dialysis care increases the use 
of surgical vascular access in HD, improves bone mineral 
metabolism parameters at dialysis initiation and reduces 
morbidity and mortality after its onset3,35. Reduction of 
total mortality, cardiovascular mortality and early mortality 
are critical in this transition phase15; hence the importance 
of investigating its predictive factors.
Faced with the problems summarized in Table III, 
the main areas for improvement are:
1.  Support of a multidisciplinary team in pre -dialysis34 
and promotion of the appropriate management of 
CKD, aiming for outcomes including patient report-
ed health and well -being, burden of care, disutility 
of care, such as recommended by the International 
Consortium for Health Outcomes36,37.
2.  Coordination of care3,35, in order to create the 
best vascular access or peritoneal access in a 
timely fashion.
3.  Inclusion of an element (such as a nurse) in the 
multidisciplinary team capable of promoting 
patient education, in order to streamline subse-
quent transitions, particularly to more autono-
mous RRT modalities34.
4.  Psychological support, integrated with the rest of 
the team, to facilitate the patient’s process of 
adaptation to his new medical condition.
  TRANSITION BETWEEN DIALYSIS 
MODALITIES
Patients often shift from dialysis modalities, so it is 
fundamental to investigate which is the best transition 
process in the course of a CKD patient’s disease, with 
better survival and less comorbidity.
Transitions from PD to HD are more frequent because 
the technique relies on a single access and the capacity 
of the patient (if not assisted). Transitions from HD to 
PD are less frequent because the vascular resources 
are progressively used with multiple procedures and, 
in the absence of capacity, the technique remains 
assisted in -centre HD. This isn’t a drawback ofPD in the 
course of patient’s disease since an elective and ade-
quate transition doesn’t reduce the patient’s surviv-
al38,39. Patients who adequately change modalities can 
benefit, in due time, from the advantages of each one. 
Conversely, persisting in one modality may be associ-
ated with decreased survival. Other than survival, clini-
cal results should also value the preservation of RRF, 
of vascular capital for future life and the best rehabilita-
tion and self -determination.
PD patients move to HD for several reasons, such as 
recurrent infections, inadequate dialysis due to loss of 
RRF, and deterioration of peritoneal membrane func-
tion40. This transition should be anticipated and 
planned, since unscheduled HD start is associated with 
increased risk of death41. It is important that these 
patients already have a mature AVF40. On the other 
hand, PD to HD transition can be very troublesome, 
especially when there is acute, often unpredictable, 
PD failure30, such as after refractory peritoneal infec-
tion or after abdominal emergency surgery, what usu-
ally implies CVC30,40. The timely prediction of PD failure 
is not easy and is a concern for nephrologists because 
it takes time to create and maturate an HD access29,41. 
Besides the type of vascular access, the timing of PD 
to HD transition may have different impact: early transi-
tions from infection episodes rarely impact overall 
survival, but late transitions associated with metabolic 
complications or inadequacy may have a negative 
impact per se.
According to Nadeau -Fredette et al.42, patient and 
technique survival of those on home HD previously 
submitted to PD is similar to those on home HD without 
previous PD. These results favour the “home -integrated 
dialysis” model and the PD to home HD transition42.
HD to PD transition may be associated not only with 
late referral and lack of education in pre-dialysis, but may 
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also be the result of HD related complications, such as 
difficulties in vascular access, severe or refractory hypo-
tension31. According to Nessim et al.31, patients who move 
from HD to PD in the first year of dialysis have a higher 
risk of death and PD failure than those who are on PD 
since the onset of RRT, with time on HD not affecting PD 
failure. This may be due to the more rapid loss of RRF in 
the initial period of HD, greater difficulty in adapting to 
PD’s self -management after a period of dependence of 
in-centre HD or by the presence of more severe pathology 
in the group of patients with an initial HD period31.
Shrestha et al43 evaluated the quality of life of 
patients on HD, continuous ambulatory PD and CNT, 
and found that PD patients have a better quality of life, 
especially in the area of mental health, possibly because 
they perceive a greater degree of independence. 
Although overall quality of life is considered to be supe-
rior in patients on PD than on HD, risks (peritonitis, 
catheter obstruction, sclerosing peritonitis versus 
access infection and sepsis, hemodynamic intolerance 
and cerebrovascular events) and the cost-effectiveness 
of each modality should be considered before the 
option for one of them43. Overall, patients’ survival on 
PD is higher in the early post -induction years and is 
similar in the long run, even showing a five-year advan-
tage after starting dialysis in the 2017 United States 
Renal Data System report44.
Compared to the general population, depression and 
decreased quality of life are prevalent among patients on 
HD35. Concerning dialytic home modalities, patients on 
continuous ambulatory PD have higher levels of depres-
sion than patients on automatic PD and home HD45.
Faced with the problems identified in this transition, 
summarized in table IV, the main areas for improvement 
are:
1.  Abolition of separate management models of 
dialysis modalities which promote care interrup-
tions and untimely transitions among HD and PD.
2.  Patient coaching in the transfer processes: antici-
pation and promotion of patient medical literacy 
and self -determination during his therapy track33.
3.  Preventive educational program for patients with 
PD to HD programmed transition, aimed at the 
HD autonomy of care and favouring the “home-
-integrated dialysis” model41.
4.  Revision of therapeutic targets, in order to inte-
grate perception of quality of life[43], frailty, men-
tal health, rehabilitation as already proposed in 
international groups36,37.
5.  Evaluation of AVF creation in PD failure high-risk 
patients40,41.
6.  Promote, whenever possible, a planned transition 
between modalities, focusing on therapeutic 
adherence and patient well -being and including 
cognitive, emotional and physical changes.
  TRANSITION FROM DIALYSIS  
TO RENAL TRANSPLANTATION
Patients start to have a more positive perception of 
their disease when they shift from dialysis to renal 
transplantation27. According to Gill et al.47, during the 
transplantation process, the transition period from 
dialysis to transplantation is associated with an 
increased risk of death, with cardiovascular disease 
being the most common cause of death. This risk can-
not be neglected but might be mitigated by adequate 
pre -transplantation evaluation and risk stratification 
towards promptly adjusted protocols. The mortality 
rate is higher in patients who receive deceased donor 
kidney than those who receive living donor kidney47.
A longer dialysis period prior to transplantation is 
associated with higher mortality, psychological burden 
and likelihood of adverse outcomes (immunological or 
otherwise) after transplantation13,47. Observational 
studies with large samples suggest that, compared to 
patients on HD, those on PD may have a higher rate of 
graft thrombosis and early graft failure (at 3 months) 
after transplantation13. Patients on PD also appear to 
have shorter waiting time to transplantation, lower rate 
of delayed graft function and better long -term graft 
survival13. However, differences in transplantation out-
comes, according to previous dialysis modality, are prob-
ably more dependent on patient related variables (often 
insufficiently controlled for) than on the modality itself.
Von der Lippe et al48 evaluated the quality of life of 
patients transitioning from dialysis to renal transplanta-
tion. Patients stated they had a better quality of life 
after transplantation, regardless of the modality of 
dialysis48. However, an improvement in quality of life 
was only sufficiently pronounced to be considered clini-
cally relevant in specific kidney domains, namely renal 
disease burden, renal disease effects, symptoms and 
work situation, in addition to overall health48. This 
improvement was evident after more than three years 
post-transplantation48. The quality of life results of 
renal transplant recipients were much lower than those 
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of the general population, except in the domains of 
body pain and mental health48. These findings are plau-
sible, since these are chronic patients who encounter 
challenges, such as short - and long -term risks of immu-
nosuppression or deterioration of graft function, which 
contributes to the perception of a lower quality of life 
than the general population48.
According to another study49 into the impact of 
transitions between dialysis and transplantation on the 
quality of life and cognition of the disease, there was 
a clinically significant improvement in quality of life, 
with perception of fewer symptoms, consequences and 
presence of disease, in addition to a sensation of great-
er control over the disease between the period before 
and after transplantation. This improvement may rein-
force a disease perception which is closer to an acute, 
instead of a chronic, event49. It should be noted that 
the very positive impact of transplantation may cor-
respond to a honeymoon effect, which is known to 
occur in the initial period of this transition48,49.
Despite the positive results of this transition of care, 
some problems are identified (summarized in table V), 
so a comprehensive and coordinated multidisciplinary 
approach is still needed to promote a planned transi-
tion49 focused on therapeutic adherence. However, 
other measures of optimization are identified as major 
in this transition period:
1.  Adoption of strategies to increase the number of 
kidney transplant recipients, in particular with the 
use of expanded criteria for kidney donors, des-
tined for dialysis patients with a higher mortality 
risk, but having a survival advantage with 
transplantation47.
2.  Adoption of strategies to improve mortality in 
wait-listed patients (through prevention, diagnosis 
and treatment of cardiovascular disease) and in 
the peri-transplant period (with reassessment of 
patients near the time of transplantation)47.
3.  Promotion of organ donation.
  TRANSITION BACK TO DIALYSIS 
AFTER RENAL TRANSPLANTATION
Advances in renal transplantation have led to more 
improvements in short -term graft survival over long-
-term survival, so that transplant failure with transition 
to dialysis will be inevitable with the end of graft sur-
vival35,49 or before, if complications develop.
One of the major threats of renal transplant patients 
is graft loss28. In the US graft failure is the fourth -leading 
cause of dialysis initiation, following diabetes, hyper-
tension and glomerulonephritis50.
Transition from transplantation to dialysis should be 
more predictable and planned, but it can be a disorga-
nized and discouraging process30. Patients with trans-
plant failure may be late referenced for dialysis evalu-
ation, even if they are followed by transplant 
nephrologists35. This may result from the disaggrega-
tion of care between dialysis and transplant centres, 
from the overvaluation of graft function preservation 
and little focus on pre-dialytic care, delays induced by 
the patient or sudden and unpredictable loss of graft 
function35.
Patients with transplant failure have a higher risk of 
mortality than patients transitioning to advanced stage 
CKD49. According to Gill et al.47, the highest mortality 
rates are reached three months after graft loss, which 
corresponds to the period in which the cause of death 
due to sepsis is of greater importance. These authors 
also found a slightly higher mortality rate in patients 
who initiated HD after graft loss than those who started 
PD47. Mortality was also higher in patients with 
deceased donor than with live donor kidney47.
Graft failure is often reflected in decreased quality 
of life and increased levels of depression49. It is 
unequivocal that dialysis resumption is a crisis process 
for the failing renal graft recipient. A study35 that com-
pared two groups of patients on dialysis found that 
patients with previous transplant failure had increased 
mortality, lower quality of life in its physical component, 
and a higher prevalence of diagnosed depression than 
non -transplanted wait-listed patients. Still in the group 
of patients with transplant failure, there was a greater 
probability of using CVC as HD access than AVF or graft, 
which is associated with an increased risk of death from 
infection35. These patients have lower serum albumin 
and haemoglobin values and higher PTH than never 
transplanted patients, although this difference is dis-
sipated with time on dialysis35. The inferior results of 
these patients may be due to prolonged immunosup-
pression leading to known risks (neoplasms, infections, 
cardiovascular complications), or to the chronic inflam-
matory state associated with the presence of dysfunc-
tional graft35. Another study49 which evaluated the 
impact of transitions between dialysis and transplanta-
tion on quality of life and illness cognitions, found a 
clinically significant decrease in quality of life, with 
perception of more symptoms, consequences and 
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presence of renal disease, in addition to a feeling of 
less control over it, after transplant failure. It should 
be noted that transplantation programs’ response and 
re-transplantation’s predicted time are highly condi-
tioning variables on quality of life perception.
Faced with the problems identified in this transition, 
summarized in table VI, the main areas for improve-
ment are:
1.  Integration of multidisciplinary care in pre-
-dialysis35,47 and reproduction of CKD manage-
ment circuit in native kidneys.
2.  Timely creation of arteriovenous vascular access 
or peritoneal access35,47.
3.  Assessment of the most appropriate strategy for 
the patient and the readiness to reduce the dose 
of immunosuppressants after graft failure (to 
decrease sepsis deaths)35,47.
4.  Evaluation of the possible adequacy of dysfunc-
tional graft nephrectomy (to prevent chronic 
inflammatory state)35,47, when the patient meets 
clinical criteria.
5.  Psychological support with patient coaching in 
crisis management and progression in self -care in 
home dialysis programs.
  TRANSITION TO END -OF -LIFE  
AND PALLIATIVE CARE
The aging of the population determines an increase 
in prevalence and incidence of chronic diseases, among 
which is CKD9. There is also an increase in the number 
of elderly patients undergoing dialysis or transplanta-
tion9. The incidence of dialysis is increasing much more 
in the elderly over 75 years old than it is in patients in 
lower age groups51,52. RRT in patients over 75 years old 
is particularly associated with uncertainty about its effec-
tiveness, given its poor results in advanced stage CKD9. 
These patients have a slow decline, which is related to 
the presence of nephropathy with insignificant protein-
uria51. In the US, one -year mortality of the elderly over 
75 years of age who started dialysis is 41%51.
In a patient, the evolution pattern of eGFR and the 
presence of comorbidities are related to dialysis 
onset51. In the US, the elderly initiate dialysis relatively 
early, often in hospital setting and many of them in the 
absence of sufficiently specific or life-threatening symp-
tomatology51. According to data from recent observa-
tional studies, dialysis does not seem to confer an 
advantage on survival, improvement of functional sta-
tus or quality of life of the elderly with stage 5 CKD, 
functional limitation, much comorbidity or malnutri-
tion51,53. Verberne et al.54 compared survival between 
patients aged 70 years or over who chose RRT and CNT. 
The average survival of those who chose RRT was higher 
than those who chose CNT54. However, the survival 
advantage associated with RRT was no longer seen in 
patients aged 80 years or older and was very subtle in 
patients of 70 or more years with high comorbidity, 
which means that CNT may be a plausible alternative 
in selected patients54. Brown et al.55 compared the 
survival of patients who opted for CNT with those who 
chose RRT and also found no survival advantage in the 
RRT patient group over 75 years of age with two or 
more comorbidities. In the Foote et al.52 systematic 
review, no significant difference was found between 
the annual survival of PD or HD in the elderly compared 
to CNT, which suggests similar annual mortalities. How-
ever, these results may vary according to the comor-
bidities of the population treated, the type of access 
and the dialysis prescriber’s ability.
The majority of patients with advanced CKD is more 
favourable to care focused on reducing pain and suf-
fering56. It is necessary to review the therapeutic end-
points, dialysis quality assessment parameters and 
treatments in geriatric patients, already proposed 
internationally36,37.
According to the KDIGO Controversies Conference 
on Supportive Care in CKD57, comprehensive conserva-
tive care should be provided by a multidisciplinary 
team3,57 and is understood as holistic, patient -centred 
care that includes “interventions to delay the progres-
sion of kidney disease and minimize the risk of adverse 
events or complications; shared decision making; active 
symptom management; detailed communication 
including advanced care planning; psychological sup-
port; social and family support; cultural and spiritual 
domains of care”57.
At this life stage, patients and clinicians still face 
institutional and structural insufficiencies in health 
services. There is a need for legal frameworks that sup-
port clinical decisions that do not always correspond 
to misplaced expectations of the family. Social support 
is also lacking.
The recognition of these limitations and the related 
economic pressure will be a first step towards obtaining 
new solutions. These will not only involve clinicians, but 
also social, institutional and community partners.
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Faced with the problems encountered, summarized 
in table VII, the main areas for improvement in this 
transition are:
1.  Assignment of a care coordinator to follow up the 
patient throughout the transition process and who 
provides the necessary information for an 
informed choice3,57.
2.  Implementation of holistic conservative care pro-
grams targeted at selected patients for symptom-
atic control and focused on quality of life55,57.
3.  Establishment of the legal framework that sup-
ports the application of these programs, giving 
the necessary support to clinical decisions.
4.  Development of social support for patients in pal-
liative care that counters the attitude of abandon-
ing this group of patients in hospitals.
5.  Gathering of social, institutional and community 
partners for the implementation of solution pro-
posals that take into account the economic 
restraints inherent in this process.
 CONCLUSION
The transitions in the course of CKD reviewed above 
are periods of great vulnerability, where critical deci-
sions are made, and which have a high propensity for 
poor outcomes. This must be well -known to be coun-
tered by anticipating the transition of care. Timely 
referral and nephrologist follow -up are fundamental 
to reduce the difficulty of predicting the need to estab-
lish RRT. There is also an important role for the primary 
care physician in the patient’s clinical follow -up and 
education.
The reality of CKD management is often a disag-
gregation of care, with deleterious consequences on 
patient’s follow -up and quality of life. Investing in tran-
sition programs with multidisciplinary teams and coor-
dination of care is fundamental to overcome this dif-
ficulty. The choice of a centralizing healthcare 
practitioner, such as a nurse capable of managing the 
disease and to whom a patient would be assigned, 
would be a strategy to improve outcomes. This care 
centralizer would manage the disease requirements, 
establish a network of communication between differ-
ent physicians, surveille the patient, promoting treat-
ment compliance, educating for future transitions and 
avoiding duplication of unnecessary procedures. It is 
fundamental to transmit to patients a realistic perspec-
tive of the treatment trajectory, which should be 
focused on planning treatment transitions so that 
patients can make a process of preparation and change 
acceptance. This review aimed to emphasize the fre-
quently documented deficiencies in the various tran-
sitional periods in CKD and to recognize its clinical, 
psychosocial and economic implications. The economic 
sustainability pressure of health services is the engine 
of better management solutions. The challenges are 
broad and the answers will not be immediate, but in 
each Unit, in each process, it is important to start, 
review, optimize and each step can mean the Change 
that is desired.
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